Surrozen, Inc./DE — Director's Dealing 2024

Apr 8, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Surrozen, Inc./DE (SRZN)
CIK: 0001824893
Period of Report: 2024-04-04

Reporting Person: Williams Charles O (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-04-04	Common Stock	P	1474	—	Acquired	1474	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-04-04	Series A Common Stock Warrant (right to buy)	$16.96	P	1474	Acquired	2029-04-04	Common Stock (1474)	Direct
2024-04-04	Series B Common Stock Warrant (right to buy)	$15.71	P	1603	Acquired		Common Stock (1603)	Direct
2024-04-04	Series C Common Stock Warrant (right to buy)	$16	P	5712	Acquired		Common Stock (5712)	Direct
2024-04-04	Series D Common Stock Warrant (right to buy)	$16	P	5712	Acquired		Common Stock (5712)	Direct

Footnotes

F1: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F2: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

F3: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

F4: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).